Cargando…
Measuring quality of life: impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials.
When assessing the value of a particular treatment, it is important to consider the impact it may have on the quality of life of those being treated. This is particularly so for cancer patients, whose life expectancy may be short. Patients with advanced colorectal cancer who participated in two inte...
Autores principales: | Anderson, H., Palmer, M. K. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2149722/ https://www.ncbi.nlm.nih.gov/pubmed/9579850 |
Ejemplares similares
-
Chemotherapy and quality of life in advanced NSCLC – reply
por: Anderson, Heather, et al.
Publicado: (2001) -
A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer.
por: Hamblin, T. J., et al.
Publicado: (1993) -
Chemotherapy and quality of life in advanced NSCLC
por: Farrugia, D, et al.
Publicado: (2001) -
Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma
por: Davies, Andrew, et al.
Publicado: (2020) -
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer
por: Robles-Zurita, José, et al.
Publicado: (2018)